Biostar Pharmaceuticals, Inc.
DelistedCIK 1418133fmd_0B24ZS234D3GBRQS5Q7N725SRRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2017, 30 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|
| Total revenues | 80 | 92 | 49 | 53 | 61 | 27 | 2 |
| Cost of revenue | 20 | 28 | 19 | 27 | 31 | 16 | 1 |
| Gross profit | 60 | 64 | 30 | 26 | 30 | 11 | 1 |
| Provision for credit losses | – | 0 | (10) | 0 | – | – | – |
| Research and development | 0 | 2 | 4 | 3 | 3 | 4 | 1 |
| Total operating expenses | 37 | 46 | 52 | 25 | 32 | 35 | 4 |
| Operating income | 24 | 18 | (22) | 1 | (1) | (24) | (4) |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | 0 | 2 | 3 | (0) | 1 |
| Income before taxes | 23 | 18 | (22) | 3 | 2 | (24) | (3) |
| Income tax expense | 6 | 6 | (2) | 2 | (3) | 1 | 3 |
| Net income from continuing operations | 17 | 12 | (20) | 1 | 5 | (25) | (6) |
| Net income | 17 | 12 | (20) | 1 | 5 | (25) | (6) |
| Net income to common shareholders | – | – | – | – | 5 | (25) | (6) |